title: [Treatment options for serious infections caused by vancomycin-resistant enterococci].
abstract: Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) Heidelberg, Universitätsklinikum Heidelberg.
authors.forename: Nico T
authors.initials: NT
authors.lastname: Mutters
authors.affiliation: Fachgebiet Nosokomiale Infektionserreger und Antibiotikaresistenzen, Nationales Referenzzentrum für Staphylokokken und Enterokokken, Abt. Infektionskrankheiten, Robert Koch-Institut, Bereich Wernigerode.
authors.forename: Guido
authors.initials: G
authors.lastname: Werner
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) Tübingen, Translational Unit for Healthcare-associated Infections, Universitätsklinikum Tübingen.
authors.forename: Evelina
authors.initials: E
authors.lastname: Tacconelli
authors.affiliation: Deutsches Zentrum für Infektionsforschung (DZIF) Heidelberg, Universitätsklinikum Heidelberg.
authors.forename: Alexander
authors.initials: A
authors.lastname: Mischnik
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D017576:Daptomycin / Q000008:administration & dosage*; D004755:Enterobacteriaceae; D019317:Evidence-Based Medicine; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D023303:Oxazolidinones / Q000008:administration & dosage*; D000078304:Tigecycline; D016896:Treatment Outcome; D065507:Vancomycin-Resistant Enterococci / Q000187:drug effects*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000078304:Tigecycline; D008911:Minocycline; D000069349:Linezolid; D017576:Daptomycin